ArticleFrontiers in psychiatry2025
Global, regional, and national burden and trends of schizophrenia among adolescents and young adults aged 15-39 years from 1990 to 2021: an analysis of the global burden of disease study 2021.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Iron dyshomeostasis in neuropsychiatric disorders.Frontiers in psychiatry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Schizophrenia imposes a substantial disability burden among individuals aged 15-39 years, yet systematic global studies are lacking. Based on data from the Global Burden of Disease (GBD) 2021 data, this study analyzed trends in schizophrenia among people aged 15-39 years at the global, regional, and national levels from 1990 to 2021. Methods: Using GBD 2021 data, we analyzed the incidence, prevalence, and disability-adjusted life years (DALYs) of schizophrenia across 204 countries and territories. Age-standardized incidence (ASIR), prevalence (ASPR), and DALY rates (ASDR) with estimated annual percentage changes (EAPC) were calculated and stratified by age, sex, and Socio-demographic Index (SDI). Decomposition analysis assessed driving factors, and a Bayesian age-period-cohort (BAPC) model was used to project trends through 2050. Results: In 2021, the global numbers of incident cases, prevalence, and DALYs of schizophrenia among people aged 15-39 increased significantly since 1990. ASIR slightly declined, while ASPR and ASDR continued rising. Regionally, South Asia had the highest absolute numbers of new cases, prevalence, and DALYs; Oceania the lowest. Australasia recorded the highest ASIR, ASPR, and ASDR; Eastern Europe had the lowest ASIR; Central Sub-Saharan Africa had the lowest ASPR and ASDR. Nationally, New Zealand had the highest ASIR, Suriname the lowest; Australia had the highest ASPR and ASDR, Somalia the lowest. ASIR showed a nonlinear relationship with SDI, rising with SDI in low (<0.46) and high (>0.61) ranges but decreasing in middle-low (0.46-0.61) range. ASPR and ASDR positively correlated with SDI. Burden was higher in males than females; 20-24 age group had the highest ASIR, 35-39 group the highest ASPR and ASDR. Decomposition showed age-structure changes mainly drove burden decreases; population growth drove increases. BAPC model predicts stable standardized rates but persistently high absolute burden globally by 2050. Conclusion: From 1990 to 2021, the global impact of schizophrenia on adolescents and young adults increased significantly, with clear variations across regions, countries, age groups, and genders by socio-demographic levels. Thus, countries should tailor mental health policies to their development and resources, prioritizing early screening, intervention, and long-term management in youth to effectively reduce the public health burden of schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.